Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND ID: Immune response to influenza vaccination in adults aged 65 years and older
2010-022882-80Phase 4Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2010
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ARCT-2138 in influenza, sponsored by Hospices Civils de Lyon. Primary endpoint: Humoral immune response and seroprotection rates to seasonal influenza vaccine strains. Started Sep 2010; status: active.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on 2010-022882-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022882-80.